Secretory carcinoma of the breast: A case report
| Autor: | Iveta Mečiarová, Petr Martinek, Zdeněk Kinkor, Kamil Pohlodek, Petr Grossmann |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Oncology
medicine.medical_specialty Breast imaging Breast surgery medicine.medical_treatment Article Benign tumor 03 medical and health sciences Breast cancer 0302 clinical medicine Internal medicine Case report Biopsy medicine skin and connective tissue diseases medicine.diagnostic_test business.industry Fluorescence in situ hybridization medicine.disease Immunohistochemistry Sectretory carcinoma 030220 oncology & carcinogenesis 030211 gastroenterology & hepatology Surgery business Secretory Breast Carcinoma |
| Zdroj: | International Journal of Surgery Case Reports |
| ISSN: | 2210-2612 |
| Popis: | Highlights • Secretory breast carcinoma is a rare tumor which accounts for < 0.15% of all breast cancers • In breast imaging it may mimic a benign tumor. • SBC is associated with a balanced translocation, t(12;15), that creates a ETV6NTRK3 gene fusion. • There is no consensus with regard to the best treatment strategy for patients with SBC. • Further research could lead to the discovery of a new targeted treatment of this tumor Introduction Secretory breast carcinoma (SBC) is a rare breast tumor which accounts for < 0.15% of all breast cancers. It was originally described as a juvenile breast carcinoma, occurring in young children and adolescent women. SBC is associated with a characteristic balanced translocation, t(12;15), that creates aETV6-NTRK3 gene fusion. Presentation of case A 52-year-old Caucasian woman had palpable lump in her right breast. After breast imaging examination (BI-RADS 4b) and preoperative core-needle biopsy with suspicion of SBC a breast conserving therapy was performed. The diagnosis of SBC was confirmed through immunohistochemistry and cytogenetic examination of the tumor. The patient is now 22 months post‑surgery and remains disease‑free. Discussion Recent studies reported that the disease occurs at a later age than previously recognized, and is associated with good long-term survival. In breast imaging it may mimic a benign tumor. Immunohistochemistry and cytogenetic analysis of the tumor are crucial for confirmation of SBC. Conclusion There is no consensus with regard to the best treatment strategy for patients with SBC. Breast conserving therapy with sentinel lymph nodes biopsy is at present the first choice treatment. Further research for a specific NTRK3 tyrosine kinase inhibitor could lead to the discovery of a new targeted treatment of this tumor. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|